Immunotherapy reduces the risk of recurrence of lung cancer

From June 4th to June 8th this year, the American Society of Clinical Oncology (ASCO) annual meeting will be held online.

Roche's blockbuster PD-L1 inhibitor significantly prolongs the "cancer-free survival" period of early-stage lung cancer patients

Lung cancer is one of the cancer types that cause the highest number of deaths in the world, and non-small cell lung cancer (NSCLC) patients account for 85% of the total number of lung cancer patients.

On May 20, Roche announced that its blockbuster PD-L1 inhibitor Tecentriq, as an adjuvant therapy, has achieved positive results in a pivotal phase 3 clinical trial for the treatment of early stage NSCLC patients.

This is the first positive phase 3 clinical result obtained by cancer immunotherapy as an adjuvant lung cancer therapy.

In a wider range of patients with stage II-IIIA NSCLC (regardless of PD-L1 expression level).

"These milestone Phase 3 data prove for the first time that cancer immunotherapy can bring clinically significant improvements in the context of adjuvant therapy for certain early-stage lung cancer patients," said Dr.

The remission rate exceeds 95%, and the Janssen/Legendary Bio CAR-T therapy has shown excellent efficacy in multiple patient groups

The CAR-T therapy ciltacabtagene autoleucel (cilta-cel) jointly developed by Janssen and Legend Bio is a CAR-T therapy targeting B cell maturation antigen (BCMA).

The ASCO abstract showed that in the Phase 1b/2 clinical trial called CARTITUDE-1, 97 patients with relapsed/refractory multiple myeloma (R/R MM) who had received 6 pre-treatments received one cilta- cel treatment.

At present, CAR-T therapy is usually used to treat patients with refractory MM who have exhausted other treatment options.

The test results showed that at a median follow-up time of 5.

Note: The original text has been deleted

Reference materials:

[1] Pivotal Phase III data at ASCO show Roche's Tecentriq helps certain people with early lung cancer live significantly longer without their disease returning.

[2] KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.

[3] Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.

[4] CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.

[5] Allogene Therapeutics CD19 Forum Highlights Positive Results from Phase 1 Studies of ALLO-501 and ALLO-501A in Relapsed/Refractory Non-Hodgkin Lymphoma and Plan to Initiate Pivotal Study in 2021.

[6] With new data, J&J's CAR-T drug benefits myeloma patients with less advanced disease.

Note: This article aims to introduce the progress of medical and health research, not to recommend treatment options.
If you need guidance on the treatment plan, please go to a regular hospital for treatment.